Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics is on track to initiate the SOTERIA Phase 2 basket trial in the fourth quarter of 2026, having secured FDA authorization and engaged a contract research organization. The company reported receipt of Fast Track Designation for lead candidate PLX-200 across all four planned indications and completed a $10 million financing to support the trial start-up and clinical milestones.
Key figures
- Drug Name
- PLX-200
- Phase Of Trial
- Phase 2
- Financing usd
- 10000000
- Sentinel group
- Yes
- Clinical trial id
- NCT07740512
- Patient age range
- 2 to 15 years
- Interim analysis weeks
- 52
- Maintenance period weeks
- 96
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.